advertisement
Konstas AG 12
Showing records 1 to 12 | Display all abstracts from Konstas AG126128 Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
İrkeç M
Expert Opinion on Investigational Drugs 2025; 34: 231-243
126278 Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Vagiakis I
Drug design, development and therapy 2025; 19: 703-714
126128 Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
Konstas AG
Expert Opinion on Investigational Drugs 2025; 34: 231-243
126278 Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Papadopoulou EP
Drug design, development and therapy 2025; 19: 703-714
126128 Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
Holló G
Expert Opinion on Investigational Drugs 2025; 34: 231-243
126278 Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Amaxilati E
Drug design, development and therapy 2025; 19: 703-714
126128 Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
Dikmetaş Ö
Expert Opinion on Investigational Drugs 2025; 34: 231-243
126278 Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Tsiropoulos GN
Drug design, development and therapy 2025; 19: 703-714
126128 Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
Algedik Tokyürek MÖ
Expert Opinion on Investigational Drugs 2025; 34: 231-243
126278 Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Konstas AG
Drug design, development and therapy 2025; 19: 703-714
126128 Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
Bozkurt B
Expert Opinion on Investigational Drugs 2025; 34: 231-243
126278 Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Panos GD
Drug design, development and therapy 2025; 19: 703-714
